Wed, Aug 07, 2024
Dr Lal PathLabs reported a 29% increase in consolidated profit after tax, reaching Rs 108 crore for Q1 FY2024, up from Rs 84 crore last year. Revenue also grew to Rs 602 crore. The board approved an interim dividend of Rs 6 per share. Shares rose 3.17% to Rs 3,268.85 on the BSE
More >
Wed, Dec 14, 2022
Meanwhile, brokerage firm UBS has maintained a buy call and set a target of Rs 2,800.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
